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Background—Increased pathologic complete response (pCR) rates observed with neoadjuvant
chemotherapy (NCT) for some subsets of patients with invasive breast cancer has prompted
interest in whether patients with pCR can be identified preoperatively and potentially spared the
morbidity of surgery. This multicenter retrospective study was performed to estimate the accuracy
of preoperative MRI in predicting pCR in the breast.
Methods—MRI at baseline and after completion of NCT plus data regarding pathologic response
was collected retrospectively from 746 women treated at 8 institutions between 2002–2011.
Tumors were characterized by immunohistochemical (IHC) phenotype into 4 categories based on
receptor expression: hormone (estrogen & progesterone) receptor (HR)-positive, human epidermal
growth factor receptor 2 (HER2) negative (n=327), HR-positive, HER2-positive, (n=148), HR-
negative, HER2-positive, (n=101), and triple-negative (HR-negative, HER2-negative, n=155).
194/249 (78%) patients with HER2-positive tumors received trastuzumab. Univariate and
multivariate analyses of factors associated with radiographic complete response (rCR) and pCR
were performed.
Results—rCR and pCR for total group were 182/746 (24%) and 179/746 (24%), respectively,
with the highest rate of pCR seen among triple-negative (57/155; 37%) and HER2 positive
(38/101; 38%) subtypes. Overall accuracy of MRI for pCR prediction was 74%. Sensitivity, NPV,
PPV, and accuracy differed significantly among tumor subtypes, with the greatest NPV in the TN
(60%) and HER2 positive (62%) subtypes.
Conclusion—Overall accuracy of MRI for predicting pCR in invasive breast cancer patients
receiving NCT was 74%. MR performance differed among subtypes possibly influenced by
differences in pCR rates between groups. Future studies will determine whether MRI in
combination with directed core biopsy improves predictive value for pathologic response.
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Background
Neoadjuvant chemotherapy (NCT) is increasingly used for the treatment of invasive, high-
risk breast cancer. The use of effective first-line chemotherapeutic agents as well as targeted
therapies such as trastuzumab for HER2+ disease in the neoadjuvant setting have resulted in
a high rate of pathologic complete response (pCR) ranging from 40–67% depending on the
study population 1–4. It remains unknown whether excision of the tumor bed in the setting of
pCR improves locoregional recurrence risk; thus there has been keen interest in determining
whether negative imaging following systemic therapy could identify a patient subset that
could be safely treated with radiation alone without surgery. Prior studies evaluating RT as
the definitive modality in treating the breast in patients with a clinical complete response to
NCT have resulted in unacceptably high locoregional failure rates5–7. This may in large part
be attributed to poor patient selection due to the fact that clinical examination to detect
residual disease or response is known to be limited8–10. A more sensitive tool to evaluate in-
breast response could more effectively identify potential candidates for RT alone following
a complete response to NCT.
One such tool is magnetic resonance imaging (MRI) which has been used with increasing
frequency in recent years due to its high sensitivity in detection of breast cancers when
compared to mammography or ultrasound11–14. The ability of a radiologic complete
response (rCR) by MRI to predict pathologic complete response (pCR) has been the subject
of active investigation. Several groups have evaluated the predictive accuracy of MRI for
assessing response to NCT and found limited correlation between rCR after completion of
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neoadjuvant chemotherapy and pCR13, 15–17. Although the performance of MRI appeared
better in some tumor phenotypes compared to others, these small retrospective studies
lacked the power to detect a significant difference among clinically distinct subsets. In this
study we sought to determine the performance of MRI following neoadjuvant chemotherapy
in a larger multi-center dataset in order to better define the accuracy of post-treatment breast
MRI in the prediction of pCR. Moreover, we wished to identify which tumor-related
variables were associated with the highest correlation between radiologic and pathologic
complete response in order to identify a patient population which may be most amenable to
treatment with whole breast radiation without surgery based on demonstration of rCR.
Materials and Methods
Patient selection
Patients with pre- and post-neoadjuvant therapy MR breast imaging were retrospectively
identified at 8 NCI-designated comprehensive cancer centers. Between January 2002 and
Feb 2011, 770 women fulfilled study criteria. Identification of patients across institutions
was stipulated by cross referencing billing codes of patients with a breast cancer diagnosis
who were treated with chemotherapy and imaged with breast MRI. Among this group were
165 patients treated on the I-SPY trials which are prospective multicenter trials of women
treated with neoadjuvant chemotherapy including radiographic and pathologic endpoints.
All participating institutions were members of the Translational Breast Cancer Research
Consortium (TBCRC) which sponsored the study, and included The University of Alabama
at Birmingham, The University of Pittsburgh Medical Center, Dana-Farber Cancer Institute,
The University of Texas MD Anderson Cancer Center, Duke University, The University of
Chicago, The University of North Carolina Chapel Hill, and the University of California San
Francisco. IRB approval for the study was obtained at each institution. In addition to pre-
and post-NCT MR imaging, eligible patients were required to have undergone definitive
surgery with pathology available for review. Patient, tumor, and treatment related variables
were entered into a secure, password-protected on-line database. Documentation of baseline
and post-treatment imaging with mammography, and ultrasound of the breast and lymph
nodes were additionally recorded.
Tumor Classification
Histological tumor types were recorded as follows: invasive ductal carcinoma (IDC), pure
invasive lobular carcinoma (ILC), invasive mammary carcinoma with ductal and lobular
features, and invasive mammary carcinoma NOS. ER and PR status (positive or negative,
with positive defined as ≥ 1%) and percentage of cells positive, and HER2 status (positive or
negative) were also collected. HER2 status was determined by local testing according to the
2007 ASCO/CAP Guidelines18. All histopathology and biomarker assessments were
performed at the individual sites. Pathologic response in the breast was categorized as: no
residual invasive disease or DCIS; no residual invasive cancer with DCIS present; and
residual invasive disease, including microscopic residual invasive disease19. To assess the
primary endpoints of sensitivity, specificity, positive predictive value (PPV), and negative
predictive value (NPV) of MRI, pathologic complete response in the breast was defined as
resolution of both invasive disease and DCIS.
Breast Imaging
All patients were required to have both baseline and post-treatment MRI to be eligible for
the study. At presentation, all patients in the cohort had an enhancing lesion on MRI
corresponding to the known biopsy-proven cancer. Baseline size of lesion defined as the
maximal diameter in a single dimension by pretreatment MRI, mammogram, and ultrasound
was recorded. A radiographic T classification was assigned based on largest imaging size by
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any modality. Patients with unknown primary lesions were excluded. Specific parameters
for dynamic contrast-enhanced (DCE) breast imaging were not defined for eligibility;
however, institutions included on this study have high levels of expertise in breast MR
imaging. Central review of MR images was not performed. Complete MR response in the
breast was defined as resolution of all areas of abnormal enhancement, mass, or distortion.
Systemic Treatment
All study patients were treated with preoperative systemic therapy. The number of cycles of
chemotherapy prior to post-treatment MRI was recorded. Patients were additionally noted as
having received trastuzumab, bevacizumab, or neoadjuvant hormonal therapy.
Statistical analysis
The sensitivity, specificity, PPV, NPV and accuracy of MRI for detecting residual disease in
the breast were estimated from the data with pCR as defined above as complete resolution of
both invasive cancer and DCIS. True negative (TN), false negative (FN), true positive (TP),
and false positive (FP) were defined as follows: TN: negative on both MRI and pathology;
FN: negative on MRI, but positive on pathology; TP: positive on both MRI and pathology;
FP: positive on pathology, but negative on MRI. Accuracy was defined as the percentage of
test results correctly identified by the test, i.e. (true positives + true negatives)/total test
results =(TP+TN)/(TP+TN+FP+FN). Accuracy of MMG and MRI was defined separately
for each individual modality (Figure 1). Combined accuracy of both modalities was scored
as accurate if both modalities predicted pCR.
Comparisons of patient subsets are based on the Chi-Square test for contingency tables.
Multivariable logistic regression was used to examine the simultaneous effects of multiple
factors. SAS (version 9.2) was used for all analyses.
Results
Patients
Data from 770 women treated at 8 tertiary NCI comprehensive cancer centers were
collected. After excluding patients with missing data (MRI response after NCT or final
pathology), 746 patients remained evaluable for the primary endpoint. The median age of
the cohort was 49 years (range 20–86). Histologic subtype rendered on initial core biopsy
was generally representative of newly diagnosed cancers. 61% were estrogen receptor (ER)
positive, 54% were progesterone receptor positive, 34% were HER2 positive. A summary of
patient and tumor characteristics is shown in Table 1.
Systemic Therapy
The most common chemotherapy regimen delivered included doxorubicin,
cyclophosphamide, and a taxane (51%), other regimens (35%), taxane and carboplatin (9%),
and doxorubicin and cyclophosphamide (5%). Five percent of patients received
bevacizumab, and 18 patients received neoadjuvant hormonal therapy only. Of 248 HER2
positive breast tumors, 194 (78%) received trastuzumab. The remaining 54 HER2 positive
breast tumors were treated prior to 2005 and did not receive trastuzumab.
Surgery
The median interval between posttreatment scans and surgery was 20 days. Definitive
surgery was mastectomy in 54% of women with or without reconstruction and breast
conservation in 46%. Nineteen percent underwent sentinel lymph node biopsy prior to
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starting systemic treatment, 42% underwent sentinel node biopsy as part of definitive
surgery and 72% had level I–II axillary node dissections.
Performance of Breast MRI
Overall, post-treatment MRI detected residual disease in the breast with a sensitivity of 83%,
specificity of 47%, PPV of 47%, NPV of 83%, and accuracy of 74%. Table 2 additionally
illustrates the performance of MRI of the breast when stratified by IHC phenotypes. There
were significant differences in sensitivity, NPV, PPV and accuracy among subtypes. NPV
was highest for patients with HR(−) HER2(+) and TN breast cancers. HER2(+) breast
tumors differed according to receipt of trastuzumab (Table 3). The addition of trastuzumab
in HER2+ breast tumors significantly increased the rate of rCR as compared with no
trastuzumab (32.5% vs 15%, respectively, p<0.0001) and was reflected in the increased rate
of pCR (33.5% vs 18.5%, respectively, p=0.01). However, this did not translate into a
difference in accuracy of MRI for predicting pCR among patients.
As a secondary aim we also assessed whether complete response on post-NCT mammogram
or ultrasound (when available) in combination with MRI increased accuracy for predicting
pCR. The accuracy of mammogram and MRI, separately and in combination for
determining pCR is listed in Figure 1. A complete response on both mammogram and MRI,
did not significantly increase the ability to detect patients with pCR over MRI alone
although as expected, rCR by mammogram (p< 0.0001) or ultrasound (p< 0.0001) were also
significantly associated with rCR on MRI (data not shown). The small number of patients
imaged post-treatment with all three imaging modalities (MRI, MMG, and ultrasound)
precluded formal evaluation of trimodality performance.
Covariates Associated with rCR and pCR
rCR and pCR for the total group were 182/746 (24%) and 179/746 (24%), respectively.
Tumor characteristics significantly associated with both complete radiographic and
pathologic response on MRI included lower radiographic baseline T classification, high
grade, ER and/or PR negative status, and HR(−)HER2(+) or TN IHC phenotype (Table 1).
On univariate analysis, race was associated with pCR but not rCR. HER2(+) breast tumors
had a trend towards increased rate of rCR (p=0.05). Treatment regimens associated with
highest rates of rCR included TC chemotherapy (p<0.0001) and use of trastuzumab
containing regimens among HER2+ breast tumors (p=0.0001). Size of tumor by
pretreatment MRI was also evaluated as a continuous variable to determine whether a
significant cutoff for rCR could be determined. Patients whose tumors were ≤ 5 cm in size
by pretreatment MR imaging had a higher chance of obtaining an rCR (p=0.09) and for
achieving a pCR in those who achieved an rCR (p = 0.06), although these findings did not
reach statistical significance (Figure 2).
Multivariate logistic regression analysis for variables significantly influencing rCR and pCR
was performed with the final model including baseline T classification, age, race, and tumor
subtype. Variables independently associated with rCR included TN or HER2+ tumor
subtype (p=0.03) and lower T stage at presentation (p=0.002). Variables independently
associated with likelihood of pCR, were TN or HER2+ tumor subtype (p<0.0001), lower T
stage (p=0.01), and African American race (p=0.0003).
Discussion
The increasingly high rate of pCR in some subsets of patients receiving NCT for invasive
breast cancer has raised the question of whether patients who achieve pCR require surgical
resection of the tumor bed, or whether the breast can be appropriately managed with
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radiation therapy alone 17. However safe omission of surgery in patients treated with
neoadjuvant therapy who achieve a rCR depends on the ability to accurately estimate pCR
preoperatively. MRI has an increased sensitivity in detecting residual disease in the breast
when compared to either mammogram or ultrasound making it a potentially useful tool in
this setting.20–25. The performance of MRI in predicting pathologic complete response in
breast cancer patients treated with NCT has been the topic of several publications over the
past several years12, 14, 15, 17, 26–36. These mostly included small single institution studies
which reported that post-treatment MRI correlated more closely with final pathology than
physical exam, mammogram, or ultrasound. However, a broad range of predictive accuracy
(58–93%) was identified. One of the best characterized studies is the I-SPY 1 trial29–31, 37
which found in 216 evaluable patients that MRI findings were a better indicator of
pathologic response to NCT than clinical assessment30. However, I-SPY 1 was
underpowered to detect significant subset differences.
The present analysis was performed to inform the feasibility of using MRI in-breast
response in a prospective trial omitting breast surgery by using radiotherapy alone in
patients who achieved a radiographic complete response after NCT. Because omission of
surgery in patients with a rCR would not be considered feasible if residual DCIS remained
in the breast, we defined pCR as resolution of both invasive disease and DCIS. This
definition of pCR has also been associated with an improvement in disease-free survival
compared to patients with resolution of invasive disease but with residual DCIS in the breast
following NCT19. We also wished to determine whether there were differences in MRI
accuracy between tumor subtypes.
We found a statistically significant difference in MRI sensitivity, NPV, PPV and accuracy
for detecting pCR among different IHC phenotypes when pCR was defined according to
either the standard definition of resolution of invasive disease only (data not shown) or more
rigorously as resolution of both invasive disease and DCIS. Previous trials have suggested
differences in the performance of MRI among different IHC phenotypes15, 31, 33, 38. We
confirmed that among patients with rCR, positive HR status and low tumor grade were most
commonly associated with residual disease at surgery, suggesting that rCR on preoperative
MRI in these patient populations should be interpreted with caution. However, it is
important to note that differences in NPV, PPV and accuracy among phenotype subsets are
impacted by varying prevalence of pCR among subtypes. Similarly, comparisons showing
significant differences among variables for complete radiographic response are reflective of
disease sensitivity to NCT rather than differing MR assessment quality across these
subtypes. Although retrospective, the present study represents the single largest analysis
addressing this question.
There were several important limitations to note. The study did not include either central
radiology review or central pathology review. However, data collection was performed
across 8 NCI comprehensive cancer centers, each with substantial expertise in MR imaging
techniques and interpretation, as well as significant expertise in surgical breast pathology.
Our goal was to create a dataset that was generalizable across different situations and
institutions, and endpoints chosen were objective and unambiguous, minimizing potential
for subjective bias. In addition, we did not collect data on markers of proliferation, such as
Ki-67, that would allow further characterization of ER+ tumors into luminal A and B
subtypes and facilitate analyses of differences between these subsets in imaging accuracy.
Finally, the specificities of the MR coil strength, contrast type, and infusion protocol for
every institution were not collected on this retrospective study and indeed, they changed
over time at each institution. While these limitations should be acknowledged, they
nevertheless allow for greater generalizability of our findings across many different clinical
settings.
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In this study, the addition of mammographic rCR to MRI in a subset of patients did not
improve the ability to detect residual microscopic disease. The role of ultrasound could not
be evaluated, as few patients in the cohort had post-treatment ultrasound in addition to MRI.
While our findings emphasize that rCR on MRI alone is not sufficient to reliably rule out
residual disease, it nevertheless remains a useful and sensitive imaging modality in this
setting, particularly among certain breast cancer subtypes.
Conclusions
The accuracy of breast MRI was 74% in prediction of pCR in patients undergoing
preoperative chemotherapy for invasive breast cancer. Sensitivity, NPV, PPV, and accuracy
of MRI for predicting pCR differed significantly among molecular breast cancer subtypes,
with the highest NPV among the HR(−)HER2(+) (62%) and TNBC phenotypes (60%). The
observed NPV of MRI overall following neoadjuvant systemic therapy does not support
using MRI alone to accurately identify patients who may be candidates for the study of
radiation alone in the context of a clinical trial. However, the high sensitivity of MRI,
particularly in HR(−) and HER2(+) phenotypes, supports its potential role in a prospective
trial to evaluate the omission of surgery in women who achieve rCR following neoadjuvant
chemotherapy, possibly in combination with other tests such as tumor bed biopsy.
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